Back to search

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

NCT03453164

PHASE1|PHASE2INTERVENTIONAL
Fukushima Medical University
41 participants
Started 2018-03-28 · Completed 2021-01-31
Status: Completed (as of 12-23-2025)

Conditions

Gastric Cancer

Linked Papers (from SciSciNet-V2)

Total Papers4
Background
2
Result
0
Derived
0
Unknown
2

Total Citations Per Year

Brief Summary

This study aims to evaluate safety and efficacy of nivolumab (anti-PD-1 antibody), which is approved as tertiary therapy, and neoadjuvant short-term limited local radiotherapy in patients with unresectable recurrent gastric cancer who progressed (intolerance or PD) after standard treatment (primary and secondary chemotherapy) and have more than one lesion assessable in diagnostic imaging (one lesion must be \>=2cm).